Glucagon-Like Peptide 1 Receptor Agonist (GLP1RA) Exposure and Outcomes in Type 2 Diabetes: A Systematic Review of Population-Based Observational Studies

INTRODUCTION: Glucagon-like peptide 1 receptor agonists (GLP1RAs) are licensed for the treatment of type 2 diabetes (T2D). They have been shown to be safe (from the cardiovascular (CV) perspective) and effective (in terms of glycaemia, and in some cases, reducing CV events) in extensive randomised c...

Descripción completa

Detalles Bibliográficos
Autores principales: Caparrotta, Thomas M., Templeton, Jack B., Clay, Thomas A., Wild, Sarah H., Reynolds, Rebecca M., Webb, David J., Colhoun, Helen M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7994483/
https://www.ncbi.nlm.nih.gov/pubmed/33635502
http://dx.doi.org/10.1007/s13300-021-01021-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7994483/
https://www.ncbi.nlm.nih.gov/pubmed/33635502
http://dx.doi.org/10.1007/s13300-021-01021-1

Ejemplares similares